FindTrial
Sign In

Investigation of the efficacy/safety and clinical dose of TAK-390MR for Erosive Esophagitis - A Phase II/III, Stratified-Randomized, Double-Blind, Parallel-Group, Multicenter Study on Efficacy and Safety of TAK-390MR by Comparison with AG-1749 in Patients with Erosive Esophagitis -

Investigation of the efficacy/safety and clinical dose of TAK-390MR for Erosive Esophagitis - A Phase II/III, Stratified-Randomized, Double-Blind, Parallel-Group, Multicenter Study on Efficacy and Safety of TAK-390MR by Comparison with AG-1749 in Patients with Erosive Esophagitis -

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220529
Enrollment
850
Registered
2008-03-14
Start date
2008-03-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjects endoscopically diagnosed erosive esophagitis

Interventions

investigational material(s) Generic name etc : TAK-390MR INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigational materi

Sponsors

Takeda Pharmaceutical Company Limited
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Subjects endoscopically diagnosed with Los Angeles grade A-D erosive esophagitis 2. Male or female subject at least 20 years of age at time of obtaining consent

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Healing rate of erosive esophagitis at 8 weeks—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026